HOWARD L JOHNSON
Nursing at Falling Crk Rd, Lake City, FL
License number
Florida 51588
Issued Date
Aug 19, 2004
Effective Date
Jun 6, 2016
Expiration Date
May 31, 2018
Category
Health Care
Type
Certified Nursing Assistant
Address
Address
2
3072 NW Falling Creek Rd, Lake City, FL 32055
1601 SW Archer Rd, Gainesville, FL 32608
1601 SW Archer Rd, Gainesville, FL 32608
Phone
(386) 288-7827
Personal information
See more information about HOWARD L JOHNSON at radaris.comName
Address
Phone
5409 Eagle Dr, Fort Pierce, FL 34951
54202 3Rd St, Astor, FL 32102
5323 Weirwood Ave, Orlando, FL 32810
536 Oak Cove Rd, Titusville, FL 32780
535 Oaks Dr APT 502, Pompano Beach, FL 33069
Professional information
Methods For Stimulating Immune Responses In A Host Through The Administration Of Superantigen Peptides Derived From Human Immunodeficiency Virus Type 1 Nef
US Patent:
5968514, Oct 19, 1999
Filed:
Oct 31, 1994
Appl. No.:
8/331454
Inventors:
Howard M. Johnson - Gainesville FL
Barbara A. Torres - Gainesville FL
Janet K. Yamamoto - Gainesville FL
Barbara A. Torres - Gainesville FL
Janet K. Yamamoto - Gainesville FL
Assignee:
University of Florida - Gainesville FL
International Classification:
A61K 3921, A61K 3800, C07K 100
US Classification:
4241881
Abstract:
The human immunodeficiency virus (HIV) contains, in addition to the canonical genes gag, pol, and env, an open reading frame in the 3' region of the genome that overlaps with the 3' long terminal repeat (LTR). Initial studies on the protein encoded by this ORF revealed a negative effect on HIV replication in vitro and this gene product was subsequently designated the negative factor, or Nef. The nef gene product is 25-29 kDa protein that localizes primarily to the cytoplasm of HIV-infected cells. The subject of this invention pertains to the discovery of a superantigen activity associated with this peptide and peptidic fragments derived therefrom. Superantigens are powerful T-cell mitogens that bind directly to major histocompatibility complex (MHC) class II molecules and form a binary complex with the variable. beta. (V. sub. beta. ) region of the T-cell antigen receptor (TCR). It was demonstrated that Nef induces the rapid proliferation of human peripheral mononuclear cells and T-lymphocyte cytokine production.
Teacher At Union County School Board
Position:
Teacher at Union County School Board
Location:
Gainesville, Florida Area
Industry:
Education Management
Work:
Union County School Board
-
Teacher
Orally-Administered Interferon-Tau Compositions And Methods
US Patent:
6372206, Apr 16, 2002
Filed:
Mar 15, 1996
Appl. No.:
08/616904
Inventors:
Jeanne M. Soos - Lansdale PA
Joel Schiffenbauer - Gaithersburg MD
Howard Marcellus Johnson - Gainesville FL
Joel Schiffenbauer - Gaithersburg MD
Howard Marcellus Johnson - Gainesville FL
Assignee:
University of Florida - Gainesville FL
International Classification:
A61K 3821
US Classification:
424 854, 930142, 435 6951, 536 2352, 530324, 530351
Abstract:
The invention includes interferon-tau (IFN ) pharmaceutical compositions useful for oral administration to treat autoimmune disorders (particularly multiple sclerosis), cell proliferative disorders and viral disease.
Orally-Administered Interferon-Tau Compositions And Methods
US Patent:
7214367, May 8, 2007
Filed:
Oct 27, 2003
Appl. No.:
10/694247
Inventors:
Jeanne M. Soos - Waltham MA, US
Joel Schiffenbauer - Gainesville FL, US
Howard Marcellus Johnson - Gainesville FL, US
Joel Schiffenbauer - Gainesville FL, US
Howard Marcellus Johnson - Gainesville FL, US
International Classification:
A61K 38/21, C07K 1/00, C07H 21/04
US Classification:
424 854, 930142, 530351, 536 2352
Abstract:
The present invention includes interferon-tau (IFNτ) pharmaceutical compositions useful for oral administration to treat cancers, autoimmune disorders (particularly multiple sclerosis), cell proliferative disorders and viral disease.
Hybrid Interferon .Tau./Type I Interferon Polypeptides
US Patent:
6174996, Jan 16, 2001
Filed:
Mar 20, 1998
Appl. No.:
9/045467
Inventors:
Howard Marcellus Johnson - Gainesville FL
Carol Hanlon Pontzer - Silver Spring MD
Carol Hanlon Pontzer - Silver Spring MD
Assignee:
University of Florida - Gainesville FL
International Classification:
C07K 14555, A61K 3821, C12N 1520
US Classification:
530351
Abstract:
The invention provides fusion proteins comprising an N-terminal region derived from an interferon-tau (IFN-. tau. ) polypeptide and a C-terminal region derived from another type I interferon polypeptide, such as IFN-. alpha. or IFN-. beta. The fusion proteins exhibit reduced cytotoxicity as compared to the corresponding unmodified type I interferons.
Antitumor Therapy Using Ovine Or Bovine Interferon-Tau
US Patent:
5958402, Sep 28, 1999
Filed:
May 31, 1995
Appl. No.:
8/455021
Inventors:
Fuller Warren Bazer - College Station TX
Howard Marcellus Johnson - Gainesville FL
Carol Hanlon Pontzer - Silver Spring MD
Troy Lee Ott - Bryan TX
Gino Van Heeke - Witterswil, CH
Howard Marcellus Johnson - Gainesville FL
Carol Hanlon Pontzer - Silver Spring MD
Troy Lee Ott - Bryan TX
Gino Van Heeke - Witterswil, CH
Assignee:
University of Florida - Gainesville FL
International Classification:
A61K 3821, C12N 1520, C07K 14555
US Classification:
424 854
Abstract:
The invention provides antitumor therapeutic methods employing bovine or ovine interferon-tau (IFN-. tau. ) proteins and polypeptides. The IFN-. tau. proteins exhibit the antiviral and antiproliferative properties characteristic of type I interferons. An advantage of the invention is that IFN-. tau. has essentially no cytotoxic effects on treated cells as does, for example, IFN-. alpha.
Superantigen Enhancement Of Specific Immune Responses
US Patent:
2005023, Oct 27, 2005
Filed:
Jun 7, 2005
Appl. No.:
11/147046
Inventors:
Howard Johnson - Gainesville FL, US
Barbara Torres - Gainesville FL, US
Scott Kominsky - Columbia MD, US
Amy Hobeika - , US
Barbara Torres - Gainesville FL, US
Scott Kominsky - Columbia MD, US
Amy Hobeika - , US
International Classification:
A61K039/00
US Classification:
424277100
Abstract:
The invention relates to superantigen mediated expansion of antigen-specific T cells for cancer and infectious agent treatment/prophylaxis. Mice were injected with inactivated B16F10 mouse melanoma cells, followed by injection with a combined SEA/SEB injection or a sham injection on days 3 and 6, followed by day 4 challenge with live melanoma cells. The SEA/SEB recipient mice survived longer post-challenge and had a higher CTLs against tumor cells than did the sham injected mice. SEA/SEB TCR activation has been reported to be independent of antigen specificity of TCRs. This invention provides a method whereby a combination of Staphylococcal enterotoxin superantigens is used to enhance specific immune responses to activating antigens to enhance immune responses against cancers and infectious agents.
Superantigen Enhancement Of Specific Immune Responses
US Patent:
2001004, Nov 29, 2001
Filed:
Mar 15, 2001
Appl. No.:
09/808718
Inventors:
Howard Johnson - Gainesville FL, US
Barbara Torres - Gainesville FL, US
Kominsky Scott - Gainesville FL, US
Barbara Torres - Gainesville FL, US
Kominsky Scott - Gainesville FL, US
International Classification:
A61K039/21, A61K039/29, A61K039/00
US Classification:
424/207100, 424/277100, 424/226100
Abstract:
The invention relates to superantigen mediated expansion of antigen-specific T cells for cancer and infectious agent treatment/prophylaxis. Mice were injected with inactivated B16F10 mouse melanoma cells, followed by injection with a combined SEA/SEB injection or a sham injection on days 3 and 6, followed by day 4 challenge with live melanoma cells. The SEA/SEB recipient mice survived longer post-challenge and had a higher CTLs against tumor cells than did the sham injected mice. SEA/SEB TCR activation has been reported to be independent of antigen specificity of TCRs. This invention provides a method whereby a combination of Staphylococcal enterotoxin superantigens is used to enhance specific immune responses to activating antigens to enhance immune responses against cancers and infectious agents.
Novel Arginine Vasopressin-Binding Peptides
US Patent:
4950650, Aug 21, 1990
Filed:
Aug 19, 1988
Appl. No.:
7/234243
Inventors:
Howard H. Johnson - Gainesville FL
Barbara A. Torres - Gainesville FL
Barbara A. Torres - Gainesville FL
Assignee:
University of Florida - Gainesville FL
International Classification:
A61K 3734
US Classification:
514 15
Abstract:
The invention concerns novel AVP-binding peptides having the formula:
Thr-Met-X-Val-Leu-Thr-Gly-Ser-Pro-B
wherein X is selected from the group consisting of Lys, Arg, and Asp; B is OH, NH. sub. 2, NHAlK, wherein Alk is lower alkyl of 1-4 carbons, inclusive. These peptides block AVP function, and, therefore, are useful in many areas among which is the control of hypertension.
Materials And Methods For Treating Autoimmune Disease
US Patent:
6083919, Jul 4, 2000
Filed:
Dec 5, 1997
Appl. No.:
8/986063
Inventors:
Howard M. Johnson - Gainesville FL
Mustafa G. Mujtaba - Gainesville FL
Jeanne M. Soos - Waltham MA
Mustafa G. Mujtaba - Gainesville FL
Jeanne M. Soos - Waltham MA
Assignee:
University of Florida - Gainesville FL
International Classification:
A61K 3800, A61K 3821
US Classification:
514 21
Abstract:
The subject invention pertains to novel methods for treating autoimmune-related diseases, such as Multiple Sclerosis (MS). One embodiment of the method of the invention comprises administering interleukin-10 (IL-10) and transforming growth factor-beta (TGF-. beta. ), in combination, to a person afflicted with or predisposed to an autoimmune disease. When administered in combination, these cytokines act in a synergistic manner as suppressor factors to inhibit the activation of self-reactive T cells that are involved in autoimmune disease.